close

  
Filter options:

Freebase Commons Metaweb System Types /type

Object is not asserted on this topic.

Freebase Commons Common /common

  • Zegerid (Santarus), manufactured drug form of Omeprazole and sodium bicarbonate, 20mg/capsule omeprazole ; 1100mg/capsule sodium bicarbonate capsule, NDC 68012-102

Freebase Commons Business /business

Freebase Commons Medicine /medicine

Section name Section URI Prominent warning Highlight text Subject manufactured drug Section LOINC code
  • false
  • Short-Term Treatment of Active Duodenal Ulcer: 20 mg once daily for 4 weeks (some patients may require an additional 4 weeks of therapy (14.1)) (2) Gastric Ulcer: 40 mg once daily for 4-8 weeks (2) Gastroesophageal Reflux Disease (GERD) (2) Symptomatic GERD (with no esophageal erosions): 20 mg once daily for up to 4 weeks Erosive Esophagitis: 20 mg once daily for 4-8 weeks Maintenance of Healing of Erosive Esophagitis: 20 mg once daily (2) Reduction of Risk of Upper Gastrointestinal Bleeding in Critically Ill Patients: (40mg oral suspension only) 40 mg initially followed by 40 mg 6-8 hours later and 40 mg daily thereafter for 14 days (2)
  • -
  • 34068-7
  • false
  • Known hypersensitivity to any components of the formulation (4)
  • -
  • 34070-3
  • false
  • Most common adverse reactions (incidence ≥ 2%) are: Headache, abdominal pain, nausea, diarrhea, vomiting, and flatulence (6) To report SUSPECTED ADVERSE REACTIONS, contact Santarus Inc. at 1-888-778-0887 or http://www.santarus.com/contact/, or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
  • -
  • 34084-4
  • false
  • Drugs metabolized by cytochrome P450 (e.g., diazepam, warfarin, phenytoin, cyclosporine, disulfiram, benzodiazepines): ZEGERID can prolong their elimination. Monitor to determine the need for possible dose adjustments when taken with ZEGERID (7) Patients treated with proton pump inhibitors and warfarin concomitantly may need to be monitored for increases in INR and prothrombin time (7) Drugs for which gastric pH can affect bioavailability (e.g., ketoconazole, ampicillin esters, iron salts, and digoxin): ZEGERID may interfere with absorption due to inhibition of gastric acid secretion (7) Voriconazole: May increase plasma levels of omeprazole (7) ZEGERID may reduce plasma levels of atazanavir and nelfinavir (7) ZEGERID may increase serum levels of tacrolimus, voriconazole, saquinavir, and clarithromycin (7) Co-administration of clopidogrel with 80 mg omeprazole may reduce the pharmacological activity of clopidogrel if given concomitantly or if given 12 hours apart (7)
  • -
  • 34073-7
  • false
  • -
  • -
  • 34088-5
  • false
  • Pregnancy: Based upon animal data, may cause fetal harm (8.1) The safety and effectiveness of ZEGERID in pediatric patients less than 18 years of age have not been established. (8.4) Hepatic Impairment: Consider dose reduction, particularly for maintenance of healing of erosive esophagitis (12.3)
  • -
  • 43684-0
  • false
  • -
  • -
  • 34089-3
  • false
  • -
  • -
  • 34090-1
  • false
  • -
  • -
  • 43680-8
  • false
  • -
  • -
  • 34092-7

Comments

Hide